TRANSARTERIAL INFUSION CHEMOTHERAPY WITH CISPLATIN PLUS S-1 FOR TREATING HEPATOCELLULAR CARCINOMA: RESULTS OF A PHASE I TRIAL

    loading  Checking for direct PDF access through Ovid

Abstract

Background

In Japan, transarterial infusion chemotherapy (TAI) with cisplatin (CDDP) is used for advanced hepatocellular carcinoma (HCC) patients, and the response rate (RR) was 33.8% in previous phase (P) II study. S-1, oral systematic chemotherapy, is also promised for advanced HCC patients, and achieved 23.1% RR in previous P-II study. The clinical feasibility and efficacy of CDDP for TAI plus S-1 in patients with advanced HCC has not yet been investigated. Thus, we carried out this trial to determine the recommended dose (RD).

Methods

Although 13 Child-Pugh class A or B patients with advanced HCC entered themselves for this P-I trial, one patient of them was excluded from this trial due to the breach of criteria. The patients received TAI with CDDP (infusion on day 1 of the courses) plus S-1 (daily oral administration on days 1–21 of the courses), every 5 weeks until disease progression.

Results

Three dose levels were used for the 12 patients. Dose-limiting toxicity was not observed in three patients at level 1 (CDDP; 65 mg/m2 and S-1; 60 mg/m2), three patients at level 2 (CDDP; 65 mg/m2 and S-1; 80 mg/m2), and seven patients at level 3 (CDDP; 65 mg/m2 and S-1;100 mg/m2); therefore, the RDs for CDDP and S-1 were considered to be 65 and 100 mg/m2, respectively (level 3). Grade 3 adverse events were reported for 10 patients and were considered to be related to the study drugs for six patients: two patients, increased alanine aminotransferase level; two patients, increased aspartate aminotransferase level; one patient, anemia; and 1 patient, decreased platelet count. The total number of treatment courses was 25, with a mean of 1.5 courses per patient (range, 1–6 courses). The median progression-free survivaltime was 73 days. The disease control rate was 58% (7 of 12); two patients (16%) achieved partial response and five (42%) had stable disease.

Conclusions

TAI with CDDP plus S-1 can be used safely with promising tumor control for treating advanced HCC. The RD to be used for a P-II study of this regimen was determined to be level 3.

Related Topics

    loading  Loading Related Articles